Compare EVO & BTZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EVO | BTZ |
|---|---|---|
| Founded | 1993 | 2006 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2021 | N/A |
| Metric | EVO | BTZ |
|---|---|---|
| Price | $3.65 | $10.74 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | 251.6K | ★ 279.4K |
| Earning Date | 11-05-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.40% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.41 |
| Revenue | ★ $887,396,457.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.52 | N/A |
| P/E Ratio | ★ N/A | $7.57 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.84 | $9.10 |
| 52 Week High | $4.80 | $11.13 |
| Indicator | EVO | BTZ |
|---|---|---|
| Relative Strength Index (RSI) | 71.06 | 39.64 |
| Support Level | $3.10 | $10.75 |
| Resistance Level | $3.23 | $10.86 |
| Average True Range (ATR) | 0.08 | 0.06 |
| MACD | 0.08 | -0.00 |
| Stochastic Oscillator | 96.87 | 13.89 |
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Blackrock Credit Allocation Income Trust is a diversified, closed-end Trust engaged in providing investment advisory and risk management solutions. Its investment objective is to seek current income, current gains, and capital appreciation. The company invests under normal market conditions, at least 80% of its assets in credit-related securities, including, but not limited to, investment-grade corporate bonds, high-yields, bank loans, preferred securities or convertible bonds, or derivatives with economic characteristics similar to these credit-related securities.